<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155427</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-186</org_study_id>
    <nct_id>NCT01155427</nct_id>
  </id_info>
  <brief_title>Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)</brief_title>
  <official_title>A Systematic Review of Literature on Common Antiretroviral Treatments Against Hepatitis B Virus (HBV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to support the clinical value of entecavir by assessing the
      relationship between viral load and histological improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systematic review of prospective clinical trials
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological improvement</measure>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <description>Patients initiating special antiviral treatments for CHB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir</arm_group_label>
    <description>Patients initiating special antiviral treatments for CHB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamivudine</arm_group_label>
    <description>Patients initiating special antiviral treatments for CHB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>telbivudine</arm_group_label>
    <description>Patients initiating special antiviral treatments for CHB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adefovir</arm_group_label>
    <description>Patients initiating special antiviral treatments for CHB</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical trial enrollees
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CHB diagnosis and no co-infection with Hep A, Hep C, Hep D, or HIV

          -  Age 16 years or older

          -  No post-transplant patients

          -  RCT, non-randomized trials, prospective cohort studies, prospectively analyses case
             series published since 2003

          -  At least one arm of trial must include monotherapy with entecavir, lamivudine,
             tenofovir, adefovir, or telbivudine

          -  Study arms must include at least 10 patients

          -  Follow-up of at least 48 weeks

          -  Published results available in English language

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/home.aspx</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>June 30, 2010</last_update_submitted>
  <last_update_submitted_qc>June 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bristol-Myers Squibb</name_title>
    <organization>Study Director</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

